In addition, it was certified that SIRT5 mediated cisplatin resistance in ovarian cancer by regulating the nuclear factor erythroid 2–related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway (Sun et al., 2019). This evidence concerns the gene HMOX1 and ovarian carcinoma.